


Cite this: *RSC Adv.*, 2020, 10, 41154

An integrated approach based on phytochemistry, network pharmacology and metabolomics reveals the mechanism of action of *Xanthium strumarium* L. for allergic rhinitis†

Tie Yao,^{‡ab} Jiankun Yan,^{‡bd} Yang Li,^b Jiabin Wang,^b Miao Qiao,^b Xintong Hu,^b Xuli Shi,^{bd} Shijie Cao^{*c} and Feng Qiu^{ib*ab}

Xanthium strumarium L. (XS) is a traditional Chinese medicine (TCM) that has been widely used in Chinese medicine prescription for allergic rhinitis (AR). However, the action mechanisms of XS on the therapeutic effects on AR remain elusive. Herein, an integrated approach of phytochemistry, network pharmacology and metabolomics was first applied to uncover the action mechanisms of XS for AR. The therapeutic effect of XS extract on AR was evaluated in rat models of ovalbumin (OVA)-induced AR. The cytokine levels in rat serum and histopathological changes of nasal mucosa were assessed after oral treatment with XS. Chemical compositions of XS were elucidated by phytochemical methods, and active ingredients were identified via ADME-TOX screening *in silico*. Network pharmacology was performed to establish and analyze the compound-target-disease network so as to find the possible mechanism of XS in treating AR. In addition, metabolomics analysis was applied to investigate the changes in the endogenous metabolite levels that result from XS treatments. As result, the XS extract significantly increased the serum concentrations of IL-2 and reduced the levels of serum IL-4, while XS could ameliorate inflammation in the nasal sub-mucosal area, indicating that XS has significant therapeutic effects on AR model rats. Furthermore, a total of 119 compounds were isolated from XS, and 59 of these compounds were identified as active ingredients through ADME-TOX screening *in silico*. An in-depth analysis of the network pharmacology implied that the active ingredients of XS could regulate the inflammatory response via "multi-component, multi-target" patterns. In combination with the results of metabolomics, we found that the active ingredients of XS have a beneficial effect on AR through regulating the metabolism of arachidonic acid, which was reflected by medicating the Fc epsilon RI signaling pathway, and the neuroactive ligand-receptor interaction pathway, as well as the key proteins in arachidonic acid metabolism, such as PTGS2, PTGS1, PTGES and ALOX5. Additionally, molecular docking showed that multiple compounds have better binding with PTGS2 and ALOX5, which might be two crucial targets. Overall, these results suggest that the treatment of XS for AR is realized by regulating the metabolism of arachidonic acid via a combination form. This study provides the basis for clinical applications of XS.

Received 5th August 2020
Accepted 21st October 2020

DOI: 10.1039/d0ra06763f

rsc.li/rsc-advances

^aSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China. E-mail: fengqiu20070118@163.com

^bSchool of Chinese Materia Medica, Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
^cTianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. E-mail: caoshijie@tjutcm.edu.cn

^dAnalysis Center of College of Science & Technology, Hebei Agricultural University, Cangzhou 061100, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra06763f

‡ These authors contributed equally to this work.

1. Introduction

Allergic rhinitis (AR) is a chronic upper respiratory inflammatory disease that is characterized by sneezing, rhinorrhea and nasal congestion.^{1,2} Owing to the increasing incidence of AR worldwide over the last decades, it has become one of the most common inflammatory diseases. Although AR did not endanger the lives of patients, the repeated recrudescence and multiple complications seriously affect the quality of peoples' lives.^{3,4} AR belongs to the immunoglobulin E (IgE)-mediated type hypersensitivity reaction, when the allergen exposures stimulate infiltration inflammatory cells within the nasal mucosa, such as eosinophils, basophils, mast cells and T cells, which release






Fig. 1 The flowchart of integrated phytochemistry, network pharmacology and metabolomics strategy for deciphering the action mechanisms of XS on AR.

multiple cytokines including prostaglandins, leukotrienes, and histamines contributing to the development of AR.⁵ In general, pharmacotherapy is a common treatment for AR, but most drugs (such as antihistamines and steroids) have serious side effects.⁶

Traditional Chinese medicine (TCM) has been widely used in China during thousands of years, which has obvious advantages of fewer side effects compared to modern medicine for treating multi-factorial diseases.⁷ Herbal medicine generally consists of tens to hundreds of components, and is capable of systematically controlling various diseases *via* potentially synergistic component interactions.⁸ However, the complex chemical composition also brings great difficulties to interpret the molecular mechanisms of herbal medicine for the treatment of diseases. Fortunately, Andrew L. Hopkins proposed the network pharmacology approach in 2007, which coincides with the tenet of the overall regulation of TCM.⁹ In recent years, as the bio-informatics and systems biology have rapidly progressed, the network pharmacology approach became a dominant paradigm to decipher the complex pharmacological mechanism of action of effective substances of Chinese medicines.

The fruits of *Xanthium strumarium* L. (XS) have been widely used in Chinese medicine prescriptions for the treatment of AR.^{10,11} XS is composed of multiple components and has been shown to possess extensive pharmacological effects on anti-inflammatory diseases.^{12,13} However, the action mechanisms of XS on the therapeutic effects on AR remain elusive. In the present work, we exert an integrated research strategy to decipher the molecular mechanism of XS in treating AR. The flow-chart of the whole study design is illustrated in Fig. 1.

2. Materials and methods

2.1 Chemicals and materials

Clarityne (drug approval number: H10970410) was purchased from Bayer Co., Ltd (Shanghai, China). Ovalbumin (OVA) was purchased from Yuanye Bio-Technology Co., Ltd (Shanghai, China). Aluminum hydroxide gel was purchased from Hat Biotechnology Co., Ltd (Xi'an, China). XS was purchased from Tong Ren Tang Co., Ltd (Beijing, China) and identified by

Professor Lijuan Zhang, Tianjin University of Traditional Chinese Medicine. A voucher specimen (herbarium no. 20151015) has been deposited in the lab. All compounds used in the experiments were isolated and identified from XS. All reagents were HPLC or analytical grade, and were purchased from Tianjin Concord Chemical Company.

2.2 Animals

Sprague-Dawley (SD) male rats (8 weeks old, weighing 180 ± 20 g) were purchased from the National Quality Inspection Center of Experimental Animals (Beijing, China; Certificate No. SCXK 2016-0006). The animals were housed under a comfortable condition of temperature (23 ± 2 °C), humidity (50 ± 5 %) and 12 hours light/dark cycle before the experiments were performed. The protocol was strictly in accordance with the Guide for the Care and Use of Laboratory Animals (US National Research Council, 2011), and approved by the Animal Experiments Ethics Committee of Tianjin University of Traditional Chinese Medicine (authorization number: TJAB-TJU20180016).

2.3 Allergic rhinitis model and treatment

After a week for acclimatization, forty-two rats were randomly divided into the following six groups: (1) the negative control group that was challenged with saline, (2) the AR group that was challenged with OVA, (3) the Clarityne oral treatment group that was treated with Clarityne dissolved in CMC-Na (0.5%) *via* intragastric administration 1 hour before intranasal OVA




Fig. 2 Schematic diagram of OVA-induced allergic rhinitis and treatment protocol. SD rats were sensitized with OVA and aluminum hydroxide every 2 days for 14 days. All groups except the negative control were sensitized with intranasal instillation with OVA on days 15 to 45. Mice were treated with XS extract *via* intragastric administration 1 hour before the intranasal OVA challenge. The negative control group was treated with saline.

challenge, and (4) the XS extract treatment groups that were treated with low-, middle- and high-dose extracts dissolved in CMC-Na (0.5%) and given intragastric administration 1 hour before intranasal OVA challenge, respectively. The procedure for allergen sensitization and challenge is summarized in Fig. 2. Briefly, rats were sensitized with OVA (0.3 mg intraperitoneally) as an antigen, which was administered together with aluminum hydroxide (30 mg) in saline (1 mL intraperitoneally) every 2 days for 14 days. All groups except the negative control were sensitized with intranasal instillation with 10 μ L of 20 mg mL⁻¹ OVA on days 15 to 30. From day 31, the Clarityne (0.9 mg kg⁻¹), low-dose extract (90 mg kg⁻¹), middle-dose extract (180 mg kg⁻¹) and high-dose extract (360 mg kg⁻¹) dissolved in CMC-Na (0.5%) were treated *via* intragastric administration 1 hour before intranasal OVA challenge, respectively.

2.4 Sample collection

Blood samples were collected from the aorta abdominalis 24 hours after the final OVA challenge, and centrifuged at 3000 rpm for 10 min, and then the supernatant was stored in a freezer at -80 °C. Rats were sacrificed after the blood collection. The heads were then stripped of the eyes, skin, and muscle, and the mandibles were excised to obtain the nasal bone parts, which were immersed in 10% neutral formalin for histological evaluation.

2.5 Histological examination

The nasal bone parts were fixed in 10% neutral formalin for 3 days, and then decalcified in 5% trichloroacetic acid for 15 days. The nasal cavity was transversely sectioned at the level of the incisive papilla of the hard palate, and the tissue block was embedded in paraffin. Some of the sections were stained with hematoxylin and eosin (H&E) to examine the tissue histology.

2.6 Compound-target-disease network construction

2.6.1 Separation and identification of chemical constituents. General experimental procedures for the separation and identification of chemical constituents are described in the ESI.† The chemical information and 2D/3D structures of chemical components were obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>).

2.6.2 ADME-TOX screening of ingredients. The properties of absorption, distribution, metabolism, excretion and toxicity (ADME-TOX) are considered as important indicators for the effectiveness of drug candidates in modern drug discovery. As a widely used Discovery Studio 2018 plug-in, the ADME-TOX descriptors are applied to identify the potential bioactive compounds from the chemical components database.

2.6.3 Target fishing of active ingredients. The potential targets of active ingredients were obtained from the Swiss Target Prediction (<http://www.swisstargetprediction.ch/>), an online tool for predicting targets based on the 2D/3D structure similarity. The directly or indirectly validated targets were extracted from the Herbal Ingredients' Targets Database (<http://lifecenter.biosino.org/hit/>).

2.6.4 AR-related genes collection. In order to better understand the mechanism of the disease, the AR related genes were collected from two resources: (1) database mining: the DrugBank (<https://www.drugbank.ca/>), TTD (<https://db.idrblab.org/ttd/>) and Ingenuity Pathway Analysis (IPA) (<http://www.ingenuity.com>) were employed to obtain AR-related genes; (2) microarray data analysis: the differential expressed genes (DEGs) were obtained by comparing GSE18574 and GSE50223, which were obtained from the GEO database (<https://www.ncbi.nlm.nih.gov/>) *via* GEO2R online analysis with a threshold of P -value ≤ 0.05 and $|\log_2 FC| \geq 1.5$. The DEGs were input into a String database to obtain protein-protein interactions (PPI). The hub genes were identified from a large PPI network by MCODE and NetworkAnalyzer. The MCODE can analyze the network based on the given parameter, and it assigns the weight to the vertex in the local neighborhood density from the dense regions by using vertex weighing, cluster prediction and optimal post-processing. The NetworkAnalyzer was used to analyze biological networks and calculate the network topology parameters, including the diameter of a network, the average number of neighbors, and the number of connected pairs of nodes. The R value was used to screen the hub genes from DEGs by the following formula:

$$R = \frac{X_i - X_i(\text{mix})}{X_i(\text{max}) - X_i(\text{mix})} \times 50\% + \frac{X_j - X_j(\text{mix})}{X_j(\text{max}) - X_j(\text{mix})} \times 50\%$$

where X_i is the degree, X_j is the betweenness centrality, and R is an indicator to evaluate the hub genes.

2.6.5 ID normalization and network construction. To normalize the gene information, different ID types were converted to Swiss-Prot accession numbers *via* the uniprot database (<http://www.uniprot.org/>). The protein-protein interaction was obtained from the String database (<https://string-db.org/>) with the threshold of interaction score ≥ 0.9 (highest confidence). To visualize and analyze the relationship between drugs and disease, the following networks were constructed: (1) compound-target network; (2) AR disease network; (3) compound-target-disease network. All of the networks were generated by Cytoscape software (Version 3.2.1).

2.6.6 Enrichment analysis. As a widely used Cytoscape plug-in, ClueGO was employed to identify the molecular function of the targets of allergic rhinitis with the threshold of P -value at 0.001. The Database for Annotation, Visualization and Integrated Discovery (DAVID) (<https://david.ncifcrf.gov/>, v6.8) was used to perform the pathway enrichment analysis of the protein in the PPI network.

2.6.7 Molecular docking. Molecular docking was performed on the Discovery Studio 2018 software. The X-ray structures of proteins were obtained from the RCSB PDB database (<https://www.rcsb.org/>). Prior to docking, all solvent molecules and co-crystallized ligands were removed from the crystallized structure of the protein, and the small molecules underwent energy minimization with the MMFF94 force field. The active sites were selected based on the ligand of the co-crystallized structure or key amino acid, and then the self-docking of the co-crystallization was employed to choose the docking method.



2.7 Metabolomics analysis

2.7.1 Sample preparation. The serum samples of the model group and middle-dose XS extract treatment group were thawed at room temperature before preparation. To precipitate the protein, 200 μL plasma samples were mixed with 800 μL acetonitrile, and then the mixture was placed on a vortex-mixer with shaking for 2 min. After centrifugation at 14 000 rpm for 10 min, the supernatant layer was transferred to a clean tube and evaporated to dryness. The residue was re-dissolved with 300 μL of 50% acetonitrile, vortexed for 2 min, and then centrifuged at 14 000 rpm for another 10 min. Finally, 200 μL supernatant was transferred to the analysis vial, and then analyzed by UPLC-Q-TOF/MS. Furthermore, serum samples were singled out from each group, which were mixed together as quality control (QC) samples. Before analysis, QC samples were continuously injected six times to equilibrate the UPLC system.

2.7.2 Liquid chromatography and mass spectrometry. Chromatographic separation was performed on an ACQUITYTM UPLC I-Class system equipped with a binary solvent system and an autosampler. The ACQUITY UPLC BEH C₁₈ column (2.1 \times 100 mm, 1.7 μm) was eluted with a mixture of 0.1% (v/v) formic acid aqueous solution (A) and acetonitrile (B). The gradient program was as follows: 5% B from 0 to 2 min, 5–50% B from 2 to 8 min, 50–95% B from 8 to 9 min, and 95% from 9 to 11 min. The flow rate was 0.3 mL min⁻¹ and the column temperature was maintained at 35 $^{\circ}\text{C}$. The mobile phase was directly delivered into the mass spectrometry apparatus.

The mass spectrometry detection was performed on a Xevo G2-S Q-TOF mass spectrometer (Waters, Milford, MA, USA) equipped with an electrospray ionization (ESI) source monitored in positive and negative ion mode. The detailed parameters were as follows: capillary voltage of 3.0 kV for positive mode and 2.5 kV for negative mode; extraction cone voltage of 3.0 V; sample cone voltage of 40 V; desolvation temperature of 400 $^{\circ}\text{C}$, and source temperature of 100 $^{\circ}\text{C}$; cone gas flow of 50 L h⁻¹; desolvation gas flow of 600 L h⁻¹. In the MS^E mode, the trap collision energy of the low-energy function was set at 0 eV, while the ramp trap collision energy of the high-energy function was set at 15–60 eV. In MS² mode, the samples were detected at the collision energy of 20 eV and 40 eV. Data in the centroid mode were set from 50 to 1000 Da.

2.7.3 Metabolomics data processing. The acquired raw data were introduced to MarkerLynx version 4.1, which allowed deconvolution, alignment, and data reduction to give a list of mass and retention time pairs with corresponding intensities for all of the detected peaks from each data file in the data set. The primary parameters were set as follows: mass range 100–1000 Da, retention time range 0–11 min, mass tolerance 0.02 Da, and noise elimination level 6. After normalization, the resultant data matrices were analyzed by principal components analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) using SIMCA-P 12.0 software after the Pareto-scaled procedure. In OPLS-DA score plots, the variables with VIP > 1 were usually regarded as candidate biomarkers.

2.8 ELISA analysis

The levels of serum cytokine (IL-2 and IL-4) were measured by commercial ELISA kits (Solarbio, China) according to the protocols provided from the manufacturer.

2.9 Statistical analysis

Data were expressed as the mean \pm standard deviation. All of the statistical analyses were carried out using SPSS software. Multiple group comparisons were performed using a one-way ANOVA test with the *post hoc* test. The Student's *t*-test was used for comparing the differences between the two groups. *P* < 0.05 was considered to indicate statistical significance.

3. Results

3.1 The efficacy of the XS extract on AR in model rats

As shown in Fig. 3B, compared with the control group, the IL-4 levels in the model group were significantly increased, while IL-2 was obviously decreased, indicating that the AR model was successfully induced. The level of IL-4 in the middle- and high-dose XS extract treatment groups were significantly reduced compared with the model group, and IL-2 was markedly increased. Simultaneously, the results of the H&E staining showed that infiltration, vascular congestion and proliferation of the inflammatory cells in the model group were significantly higher than those in the control group, but the XS extract could significantly ameliorate these abnormalities (Fig. 3A). These data suggest that 75% XS extract could improve inflammation in the AR rat model.

3.2 Chemical constituents of XS

A total of 119 chemical compositions were isolated and identified from 75% XS extract, which were divided into seven classes




Fig. 3 The effects of low-dose (90 mg kg⁻¹), middle-dose (180 mg kg⁻¹) and high-dose (360 mg kg⁻¹) of XS extract on AR in model rats. (A) Histological changes of the nasal sub-mucosal area were observed 15 days after administration of XS (H&E staining, 200 \times magnification). (B) ELISA evaluation of serum concentrations of IL-2 and IL-4 in experimental animal groups. The values are expressed as the mean \pm S.D. ##*P* < 0.01 vs. control group, **P* < 0.05, ***P* < 0.01 vs. model group.






Fig. 4 The ADME-TOX screening of ingredients. The blue dots represented the ingredients from XS. Plot of the polar surface area (PSA) vs. log *P* for tested compounds showing the 95% and 99% confidence limit ellipses corresponding to the blood brain barrier and intestinal absorption models.

of compounds in combination with the information available, including 19 anthraquinones, 44 phenylpropanoids, 18 phenolic acids, 10 flavonoids, 9 alkaloids, 6 triterpenes and steroids, as well as 13 others. Integrating the above data, these compounds constituted the chemical components database, their detailed classification and structures in Fig. S1.†

3.3 Compound-target network construction

The 59 potential active ingredients were filtered out from the 119 components of XS by the criterion of ADME-TOX on the Discovery Studio 2018 software (Fig. 4). Subsequently, 345 targets were predicted to be associated with the 59 potential active ingredients. In order to visualize the relationship between the potential active compounds and targets, the compound-target network was constructed. The network comprised 404 nodes (59 compounds and 345 potential targets) and 2419 edges (compound-target and protein-protein interactions) (Fig. 5).

3.4 Disease network construction

The genes associated with AR were collected from two sources: first, 83 genes related to AR were collected from DrugBank, TTD database and IPA software. Second, the microarray data analysis

was applied to explore the genes that were associated with AR. A total of 201 overlapping DEGs were screened out, including 150 up-regulated and 51 down-regulated DEGs, as shown in Fig. 6A and B. The volcano plot and heatmap showed the fold-changes and DEGs between the two groups (Fig. 6C–E). The DEGs were submitted to the String database to obtain the PPI network. Then, MCODE plug-in was used to perform the clustering analysis for the PPI network (Fig. 7), and the top three modules containing 40 nodes were screened out from the PPI network. In the meantime, NetworkAnalyzer was used to calculate the topology parameters of the PPI network of DEGs. The nodes with a high degree and large betweenness centrality value were considered as important genes in the network. The top 25 genes were screened out *via* the *R* value, which was used to evaluate the importance of the genes as defined in the *R* equation, and as shown in Table 1. The 22 overlapping genes between MCODE




Fig. 6 Identification of 201 DEGs from GSE18574 and GSE50223. (A and B) In the Venn diagrams, the co-expression of up-regulated and down-regulated genes in GSE18574 and GSE50223. (C and D) Volcano plot of differentially expressed genes. Red: up-regulated; green: down-regulated. (E) Heatmap of DEGs in GSE18574 and GSE50223.




Fig. 5 Compound-target network. The diamond nodes represented the potentially active compounds, and the circular nodes represented the potential protein targets. The different colored diamonds represented the different types of compounds.






Fig. 7 Top three modules from the PPI network of DEGs. Red: up-regulated; green: down-regulated.

and NetworkAnalyzer were considered to be the significant genes for AR. Finally, 104 proteins were collected as the targets associated with AR, and were used to construct the disease network, as shown in Fig. 8C. Subsequently, ClueGO was used to further identify the molecular functions of these 104 targets. The molecular functions mainly consisted of ten groups, such as the alpha-adrenergic receptor activity, G protein-coupled amine receptor activity and serotonin binding, which indicated that most targets were related to the stress response, signaling receptor activity and serotonin binding (Fig. 8A and B). To further explore the genes associated with AR, these

targets were submitted to the String database to extend with a threshold value greater than 0.9 (highest confidence). Finally, an expanded PPI network associated with AR was constructed, as shown in Fig. 8D, and was composed of 511 nodes (104 direct correlations and 407 indirect correlations) and 9796 edges.

3.5 Compound-target-disease network construction and network topological analysis

The compound-target network and AR disease network were merged by Cytospace software to construct a compound-target-disease network that was composed of 166 nodes (52 compounds and 114 targets) and 388 edges, as shown in Fig. 9. The composite network illuminated the relationship among the herbs, candidate compounds, and AR. Upon further analysis of the compound-target-disease network, we found that 35 compounds had a degree value ≥ 3 , which indicated that most compounds interacted with the multi-target. For instance, apigenin (flavonoid 4) interacted with 26 targets, stylopine (alkaloids 1) interacted with 13 targets, and atractyligenin (others 13) interacted with 11 targets. Meanwhile, we found some gene targets that were hit by multi-compounds, such as PTGE2 and ALOX5, which were targeted by 11 and 14 compounds, respectively. In addition, CDK1 and CDK2 were not hit by multiple

Table 1 Top 25 targets of AR with degree and betweenness centrality

Swiss prot	Genes/proteins	Description	Up/down	Degree	BC ^a	R
Q12834	CDC20	Cell division cycle protein 20 homolog	Up	50	0.33696	0.6584
P20248	CCNA2	Cyclin-A2	Up	53	0.13701	0.5761
P02649	APOE	Apolipoprotein E	Down	4	0.90000	0.5288
P16410	CTLA4	Cytotoxic T-lymphocyte protein 4	Up	3	0.83333	0.4822
P14635	CCNB1	G2/mitotic-specific cyclin-B1	Up	45	0.07355	0.4639
O95067	CCNB2	G2/mitotic-specific cyclin-B2	Up	44	0.03752	0.4343
O43683	BUB1	Mitotic checkpoint serine/threonine-protein kinase BUB1	Up	38	0.02227	0.3681
Q96GD4	AURKB	Aurora kinase B	Up	37	0.02088	0.3578
P11388	TOP2A	DNA topoisomerase 2-alpha	Up	37	0.02031	0.3574
Q13257	MAD2L1	Mitotic spindle assembly checkpoint protein MAD2A	Up	36	0.01816	0.3466
Q53HL2	CDCA8	Borealin	Up	34	0.00806	0.3218
O95235	KIF20A	Kinesin-like protein KIF20A	Up	32	0.00486	0.3008
Q8IZT6	ASPM	Abnormal spindle-like microcephaly-associated protein	Up	31	0.02118	0.3002
O14965	AURKA	Aurora kinase A	Up	31	0.00491	0.2912
Q99661	KIF2C	Kinesin-like protein KIF2C	Up	31	0.00397	0.2907
P43489	TNFRSF4	Tumor necrosis factor receptor superfamily member 4	Up	2	0.50000	0.2874
O15392	BIRC5	Baculoviral IAP repeat-containing protein 5	Up	30	0.01214	0.2856
Q9BXS6	NUSAP1	Nucleolar and spindle-associated protein 1	Up	29	0.00303	0.2709
Q02224	CENPE	Centromere-associated protein E	Up	28	0.00210	0.2608
P33981	TTK	Dual specificity protein kinase TTK	Up	27	0.00281	0.2516
Q02241	KIF23	Kinesin-like protein KIF23	Up	27	0.00279	0.2516
P49454	CENPF	Centromere protein F	Up	26	0.00118	0.2410
Q53EZ4	CEP55	Centrosomal protein of 55 kDa	Up	25	0.00429	0.2332
P01034	CST3	Cystatin-C	Down	2	0.40000	0.2318
P33992	MCM5	DNA replication licensing factor MCM5	Up	23	0.03189	0.2293

^a BC was the abbreviation of betweenness centrality.






Fig. 8 AR disease network and ClueGO analysis of the disease targets. GO terms are represented as nodes, and the node size represents the term enrichment significance. Functionally related groups are partially overlapped. (A and B) Representative molecular function interactions among targets. (C) The AR disease network. (D) The expanded AR disease network.




Fig. 9 Compound-target-disease network. The node size represents the value of the degree. The diamond nodes represented the potential active compounds, and the different colored diamonds represented the different types of compounds. The circular nodes represented the potential protein targets. Green: directly associated with AR. Pink: indirectly associated with AR.

compounds; however, they had a high value degree, which indicated that they play important roles in the link of the PPI network.

Before further analysis of the compound-target-disease network, molecular docking was applied to verify the

interaction between the important targets and compounds. Molecular docking was performed according to the value of the degree with PTGS2 and ALOX5 as the crucial targets. As shown in Fig. 10, the binding patterns between the compounds and the target were good. Furthermore, previous numerous reports indicated that most compounds in the network regulated the related proteins, which indicated that the compound-target-disease network was reliable.^{14–19} Subsequently, the 114 targets in the compound-target-disease network were submitted to the DAVID v6.8 database to further identify the biological functions. In Fig. 11, the results were divided into four strata: molecular function, biological process, cellular component and KEGG pathway analysis. In particular, the molecular functions mainly consisted of drug binding, G-protein coupled acetylcholine receptor activity, G-protein coupled adenosine receptor activity and cyclin-dependent protein serine/threonine kinase activity, which indicated that most targets were related to the signaling receptor activity and drug binding. Additionally, the biological process of the targets was mainly related to the inflammatory response, positive regulation of the nitric oxide biosynthetic process and response to the drug. These results suggest that the targets are related to AR at different levels, indicating that XS might produce a therapeutic effect on AR through multiple ways.

3.6 Metabolite identification and metabolic pathway

Metabolites were identified by the method described in Metabolomics data processing. These MSMS fragment ions of





Fig. 10 Three-dimensional model of the potential active compounds within the binding domains of PTGS2 (PDB code: 3O8Y) and ALOX5 (PDB code: 5IKR).

the metabolites were compared to the human metabolome databases (HMDB: <http://www.hmdb.ca/>). Eight biomarkers were confirmed, and the detailed information is shown in Table




Fig. 11 GO enrichment analysis of the AR-associated genes in molecular function, biological process, cellular component and KEGG pathway analysis. (A) The results of the GO enrichment analysis. The y-axis represents the GO terms. The intensity of the color depends on the $-\log_{10}(P \text{ value})$, and red means a higher significant difference. The size of the point shows the number of genes. (B) The name corresponds to the GO terms.

2. The interrelated pathways of the above-mentioned biomarkers were analyzed by Metaboanalyst 4.0 (<https://www.metaboanalyst.ca/>). Finally, the changes in the metabolism of arachidonic acid, linoleic acid and α -linolenic acid were revealed after XS treatment.

4. Discussion

XS has been used as a TCM for treating AR, which has a good curative effect, and fewer side effects compared to hormone drugs. However, XS is similar to other TCMs and has a complex chemical composition, which makes it hard to understand its molecular mechanism, therefore limiting its worldwide use. So far, only a few studies showed that the mechanism of XS against AR might be associated with the inhibition of Ca^{2+} uptake and histamine release, increase cAMP, and inhibition of pro-inflammatory cytokines.²⁰ In recent years, network pharmacology has been used in many successful cases for revealing the molecular mechanism of TCM.^{21,22} Although network pharmacology has advantages in elucidating the mechanisms of TCM, there are still some limitations. In most studies, the active ingredients are obtained from the herb database, while ingredients that are not recorded are often neglected, resulting in the primary ingredients and targets predicted by network pharmacology possibly deviating from the truth. Herein, we first apply the phytochemistry combined with network pharmacology and metabolomics to reveal the action mechanisms of XS in treating AR.

In the current study, the therapeutic effect of XS on AR was first validated in animal models. The results of the animal experiment showed that the XS extract has a good therapeutic effect on AR, which provided a strong basis for subsequent studies. Subsequently, the chemical compositions of XS were elucidated by phytochemical methods. Among XS, 59 compounds were screened out by *in silico* ADME-TOX as potentially active ingredients. A combination of network pharmacology and metabolomics was performed to speculate the action mechanisms of XS in treating AR.

The compound-target-disease network showed that most compounds interacted with multi-targets, consistent with the concept of “multi-component, multi-target” in TCM. GO enrichment analysis uncovered the molecular mechanisms of XS in the treatment of AR. The GO BP terms showed that the gene targets were mainly enriched in the inflammatory response, cyclooxygenase pathway, and positive regulation of the nitric oxide biosynthetic process, which indicate that XS could participate in the regulation of the inflammation response in the treatment of AR. Consistent with the GO BP terms, in comparison with the model group, XS significantly increased the level of IL-2, while reducing the level of IL-4 in the animal experiment.

Furthermore, the pathway enrichment analysis is mainly involved with the Fc epsilon RI signaling pathway, Toll-like receptor signaling pathway and T cell receptor signaling pathway. Numerous reports demonstrated that the allergens could activate the Toll-like receptor signaling pathway, T cell receptor signaling pathway and B cell receptor signaling



Table 2 The endogenous differential metabolites between the model group and middle-dose XS extract treatment group

No.	T_R (min)	Ion form	m/z	Formula	Metabolite	VIP	P -Value	Trend	
1	10.39	$[M + H]^+$	758.5693	$C_{42}H_{80}NO_8P$	PC (14:0/20:2 (11Z, 14Z))	5.797	0.0161	↓	25.72
2	1.39	$[M - H]^-$	260.0214	$C_9H_{11}NO_6S$	2-Methoxyacetaminophen sulfate	2.564	0.0002	↑	2.44
3	2.9	$[M - H]^-$	212.0033	$C_8H_7NO_4S$	Indoxyl sulfate	24.025	0.0136	↓	2.44
4	4.04	$[M - H]^-$	333.2074	$C_{20}H_{30}O_4$	15-Deoxy-PGD ₂	2.31	0.0143	↓	10.9
5	4.53	$[M - H]^-$	335.2224	$C_{20}H_{32}O_4$	5,20-DiHETE	7.015	0.0002	↑	2.64
6	4.66	$[M - H]^-$	337.2401	$C_{20}H_{34}O_4$	12-Keto-tetrahydro-leukotriene B ₄	3.765	0.0017	↑	3.83
7	5.23	$[M - H]^-$	333.2056	$C_{20}H_{30}O_4$	5-Oxo-12-HETE	2.884	0.0284	↑	6.07
8	8.34	$[M - H]^-$	329.2480	$C_{22}H_{34}O_2$	Docosapentaenoic acid	5.885	0.0001	↑	2.23

pathway, causing the aggregation of the T cells and B cells, thereby activating the Fc epsilon RI signaling pathway, and then results in inflammation.^{23,24} The results indicate that the treatment of XS against AR is a synergistic effect. In addition, we found some gene targets with a high value of degree in the network, which play key roles in treating AR. For instance, PTGS2 is responsible for the production of inflammatory prostaglandins, and ALOX5 is a key enzyme catalyzing the first step in leukotriene biosynthesis.^{25,26} As these targets are involved in the production of inflammatory mediators, we speculate that XS may inhibit the production of inflammatory mediators to treat AR. Subsequently, the results of the metabolomics analysis proved our hypothesis. Eight differential metabolites were identified between the model group and treatment group, which are mainly enriched in the arachidonic acid (AA) metabolism pathway. Arachidonic acid, as a precursor of bioactive substances, is involved in the regulation of various biological functions. The main metabolic pathway of AA is the cyclooxygenase (COXs) pathway, lipoxygenase (LOX) pathway and CYP-450 pathway in the organism, and the metabolites of AA play an important role in the inflammatory process.^{27–30} Therefore, the regulation of enzyme activity in the AA metabolism pathway can regulate inflammation, and the inflammatory response and process.^{31,32} Subsequently, we further reconstructed a metabolic network based on the above results, as shown in Fig. 12. This metabolic network indicates that XS can interact with multiple enzymes in the AA metabolic pathway to regulate the metabolism of AA. Taken together, we conclude

that the treatment of XS for AR is realized by regulating the arachidonic acid metabolism *via* a combination form. In addition, we found some targets related to cell proliferation, such as CDK1, CDK2, CDK4, TTK and ADRA1D. Whether these targets are related to the treatment of AR with XS needs to be further investigated.

5. Conclusions


In the current work, a comprehensive integration of phytochemistry, network pharmacology, and metabolomics was taken first to systematically investigate the molecular mechanism of XS for AR. This integrated approach successfully illuminates the molecular mechanism of XS in treating AR. The present work may provide valuable evidence for further clinical applications of XS.

Author contributions

Feng Qiu, Shijie Cao and Tie Yao conceived and designed the study. Tie Yao, Jiankun Yan, Yang Li, and Jiaxin Wang performed most of the experiments. Tie Yao, Miao Qiao, and Xintong Hu analyzed and interpreted the data. Xuli Shi provided the technical support. Tie Yao drafted the article. All authors made the final approval of the version to be submitted.

Abbreviations

AA	Arachidonic acid
ADME-TOX	Absorption, distribution, metabolism, elimination and toxicity
ALOX5	Arachidonate 5-lipoxygenase
AR	Allergic rhinitis
BC	Betweenness centrality
BP	Biological process
CDK	Cyclin-dependent kinase
DEGs	Differential expressed genes
ELISA	Enzyme-linked immunosorbent assay
GO	Gene ontology
H&E	Hematoxylin and Eosin
IgE	Immunoglobulin E
IL-2	Interleukin-2
IL-4	Interleukin-4
MMFF	Merck molecular force field

**Fig. 12** The metabolic network of XS for the treatment of AR.

OVA	Ovalbumin
PPI	Protein–protein interaction
PTGES	Prostaglandin E synthase 3
PTGS1	Prostaglandin G/H synthase 1
PTGS2	Prostaglandin G/H synthase 2
TCM	Traditional Chinese medicine
TTK	Dual specificity protein kinase TTK
XS	<i>Xanthium strumarium</i>

Conflicts of interest

The authors declare that they have no conflict of interest.

Notes and references

- M. S. Blaiss, E. O. Meltzer, M. J. Derebery and J. M. Boyle, *Allergy Asthma Proc.*, 2007, **28**(Suppl 1), S4–S10.
- L. Klimek, P. Hogger and O. Pfaar, *HNO*, 2012, **60**, 611–617.
- M. Westman, P. Stjarne, A. Asarnoj, I. Kull, M. van Hage, M. Wickman and E. Toskala, *J. Allergy Clin. Immunol.*, 2012, **129**, 403–408.
- P. W. Hellings and J. L. Ceuppens, *Allergy*, 2004, **59**, 914–919.
- J. S. Cho, J. H. Kang, I. H. Han, J. Y. Um, I. H. Park, S. H. Lee and H. M. Lee, *Clin. Exp. Otorhinolaryngol.*, 2015, **8**, 243–249.
- N. P. Tran, V. John and M. S. Blaiss, *Allergy, Asthma Immunol. Res.*, 2011, **3**, 148–156.
- F. Cheung, *Nature*, 2011, **480**, S82–S83.
- S. Li and B. Zhang, *Chin. J. Nat. Med.*, 2014, **11**, 110–120.
- A. L. Hopkins, *Nat. Chem. Biol.*, 2008, **4**, 682–690.
- Y. Y. Kung, Y. C. Chen, T. J. Hwang, T. J. Chen and F. P. Chen, *Allergy*, 2006, **61**, 1316–1318.
- S. K. Huang, Y. L. Ho and Y. S. Chang, *J. Ethnopharmacol.*, 2015, **173**, 212–216.
- H. Jiang, L. Yang, G. X. Ma, X. D. Xing, M. L. Yan, Y. Y. Zhang, Q. H. Wang, B. Y. Yang, H. X. Kuang and X. D. Xu, *Fitoterapia*, 2017, **117**, 11–15.
- Y. S. Shi, Y. B. Liu, S. G. Ma, Y. Li, J. Qu, L. Li, S. P. Yuan, Q. Hou, Y. H. Li, J. D. Jiang and S. S. Yu, *J. Nat. Prod.*, 2015, **78**, 1526–1535.
- J. B. Park, *J. Nutr. Biochem.*, 2009, **20**, 800–805.
- R. Rezg, B. Mornagui, S. El-Fazaa and N. Gharbi, *Toxicology*, 2008, **250**, 27–31.
- A. M. Vetrano, D. E. Heck, T. M. Mariano, V. Mishin, D. L. Laskin and J. D. Laskin, *J. Biol. Chem.*, 2005, **280**, 35372–35381.
- S. Yano, D. Umeda, T. Yamashita, Y. Ninomiya, M. Sumida, Y. Fujimura, K. Yamada and H. Tachibana, *Eur. J. Nutr.*, 2007, **46**, 257–263.
- M. Nardini, F. Leonardi, C. Scaccini and F. Virgili, *Free Radic. Biol. Med.*, 2001, **30**, 722–733.
- S. I. Jang, B. H. Kim, W. Y. Lee, S. J. An, H. G. Choi, B. H. Jeon, H. T. Chung, J. R. Rho, Y. J. Kim and K. Y. Chai, *Arch Pharm. Res.*, 2004, **27**, 923–929.
- W. X. Fan, L. X. Fan, C. Y. Peng, Q. Zhang, L. Wang, L. Li, J. L. Wang, D. Y. Zhang, W. Peng and C. J. Wu, *Molecules*, 2019, **24**, 359.
- Y. B. Li, Y. M. Li, W. L. Lu, H. B. Li, Y. M. Wang, H. M. Luo, Y. Y. Wu, W. Y. Dong, G. Bai and Y. J. Zhang, *Front. Pharmacol.*, 2018, **9**, 597.
- C. Wang, Q. Ren, X. T. Chen, Z. Q. Song, Z. C. Ning, J. H. Gan, X. L. Ma, D. R. Liang, D. G. Guan, Z. L. Liu and A. P. Lu, *Front. Pharmacol.*, 2018, **9**, 841.
- M. Volkova, Y. Zhang, A. C. Shaw and P. J. Lee, *J. Gerontol. Biol. Med. Sci.*, 2012, **67**, 247–253.
- J. Bousquet, P. K. Jeffery, W. W. Busse, M. Johnson and A. M. Vignola, *Am. J. Respir. Crit. Care Med.*, 2000, **161**, 1720–1745.
- S. F. Kim, D. A. Huri and S. H. Snyder, *Science*, 2005, **310**, 1966–1970.
- N. C. Gilbert, S. G. Bartlett, M. T. Waight, D. B. Neau, W. E. Boeglin, A. R. Brash and M. E. Newcomer, *Science*, 2011, **311**, 217–219.
- T. G. Brock, R. W. McNish and M. Peters-Golden, *J. Biol. Chem.*, 1999, **274**, 11660–11666.
- M. Abramovitz, E. Wong, M. E. Cox, C. D. Richardson, L. I. Chun and P. J. Vickers, *Eur. J. Biochem.*, 1993, **215**, 105–111.
- Z. M. Chu, K. D. Croft, D. A. Kingsbury, J. R. Falck, K. M. Reddy and L. J. Beilin, *Clin. Sci.*, 2000, **98**, 277–282.
- S. E. Wenzel, *Pharmacotherapy*, 1997, **17**, 3S–12S.
- J. Hellmann, Y. Tang, M. J. Zhang, T. Hai, A. Bhatnagar, S. Srivastava and M. Spite, *Prostag. Other Lipid Mediat.*, 2015, **116–117**, 49–56.
- L. Li, H. Zeng, L. Shan, X. Yuan, Y. Li, R. Liu and W. Zhang, *J. Ethnopharmacol.*, 2012, **143**, 732–739.

